Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Phase 3

Completed

• Conditions: Hepatitis B
• Interventions: Biological: Engerix™-B; Biological: HBV-MPL vaccine 208129

• Registration Number: NCT00697554
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to enroll pre-liver transplant patients who will be vaccinated with either the novel adjuvanted HBV vaccine or double doses of Engerix™-B. The immunogenicity and safety of the novel adjuvanted vaccine will be compared to Engerix™-B as the control vaccine

Detailed Description

At the time of conduct of this study, the sponsor GlaxoSmithKline was known by its former name SmithKline Beecham

Study Timeline

• Study Start: 2000-01
• Primary Completion: 2002-05
• Study First Submitted: 2008-06-12
• Study First Submitted QC: 2008-06-13
• Study First Posted: 2008-06-16
• Status Verified: 2016-09
• Last Update Submitted: 2016-09-08
• Last Update Posted: 2016-09-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 93

Inclusion Criteria

• A male or female ≥ 18 years of age at the time of the first vaccination.
• Written informed consent obtained from the subject.
• Seronegative for anti-HBs-antibodies, anti-HBc-antibodies & HBsAg.
• If the subject is female, she must be of non-childbearing potential or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions for 30 days prior to vaccination, have a negative pregnancy test and must agree to continue such precautions for two months after completion of the vaccination series.
• Documented case of liver failure, such that the patient will require an eventual liver transplant

Exclusion Criteria

• Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
• Planned administration/ administration of a vaccine not foreseen by the study protocol during the period starting from 30 days before each dose of vaccine and ending 30 days after.
• Previous vaccination against hepatitis B (whether or not a non-responder to vaccination).
• Previous vaccination with an adjuvant system containing MPL®.
• History of hepatitis B infection.
• Known exposure to hepatitis B virus within 6 weeks.
• Previously confirmed human immunodeficiency virus (HIV) infection.
• A family history of congenital or hereditary immunodeficiency.
• Immunosuppression caused by the administration of parenteral steroids or chemotherapy.
• Suspected or confirmed multiple sclerosis in the subject (applicable to Centres 011, 012, 013 and 014/ France only).
• History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
• Acute, intercurrent disease at the time of enrollment.
• Oral/axillary temperature of ≥ 37.5°C (≥ 99.5°F).
• Administration of immunoglobulins and/or any blood products within one month preceding the first dose of study vaccine or planned administration/ administration during the study period.
• Pregnant or lactating female

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group B	Engerix™-B	-
Group A	HBV-MPL vaccine 208129	-

Primary Outcome Measures

Name	Time	Method
Anti-HBs antibody concentrations	At Day 28

Secondary Outcome Measures

Name	Time	Method
Occurrence, intensity and relationship to vaccination of unsolicited symptoms	During a 30 day follow-up period after vaccination
Occurrence, intensity and relationship to vaccination of serious adverse events (SAEs)	During the study period
Occurrence, intensity and relationship to vaccination of solicited local and general signs and symptoms	During a 4 day follow-up period after vaccination
Anti-HBs antibody concentrations	At d21, d28, d56, M6-12, 1M after booster dose